Neurocrine Biosciences Inc vs STMicroelectronics NV — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while STMicroelectronics NV trades at $65.56 (market cap $55.80B). The key difference: STMicroelectronics NV is far larger — about 3.2× Neurocrine Biosciences Inc's market cap, and STMicroelectronics NV pays a 0.58% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | STM | |
|---|---|---|
Market Cap | $17.40B | $55.80B |
Sector | Health | Financials |
52-Week High | $180.55 | $79.91 |
52-Week Low | $123.10 | $21.20 |
Enterprise Value | $16.49B | $54.01B |
Dividend Yield | — | 0.58% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →